West Pharmaceutical Servs Raises FY2025 Adj EPS Guidance from $6.15-$6.35 to $6.65-$6.85 vs $6.29 Est; Raises FY2025 Sales Guidance from $2.945B-$2.975B to $3.040B-$3.060B vs $2.961B Est

Author: Benzinga Newsdesk | July 24, 2025 06:02am

Full-Year 2025 Financial Guidance

• The Company is increasing its full-year 2025 net sales guidance range to $3.040 billion to $3.060 billion, up from previous guidance of $2.945 billion to $2.975 billion.
  • Net sales guidance includes an estimated full-year 2025 tailwind of approximately $59 million based on current foreign currency exchange rates, compared to previous guidance of a headwind of approximately $5 million.
  • Organic net sales growth is expected to be approximately 3% to 3.75%, up from the previous guidance range of 2% to 3%.
• The Company is increasing its full-year 2025 adjusted-diluted EPS guidance range to $6.65 to $6.85, up from the previous range of $6.15 to $6.35.
  • Full-year adjusted-diluted EPS guidance assumes a $0.27 tailwind based on current foreign exchange rates, compared to previous guidance of no impact.
  • This guidance includes EPS of $0.04 associated with first-half 2025 tax benefits from stock-based compensation.
  • Our updated adjusted-diluted EPS guidance incorporates our estimate of $15 to $20 million for the net impact of recently implemented tariffs.
  • For the remaining quarters of the year, our adjusted-diluted EPS guidance range assumes a tax rate of approximately 21% and does not include potential tax benefits from stock-based compensation. Any tax benefits associated with stock-based compensation beyond those recorded in the first-half of 2025 would provide a positive adjustment to our full-year adjusted-diluted EPS guidance.
• Full-year 2025 capital spending guidance is unchanged and is expected to be $275 million.

Posted In: WST